Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Business Activity | PASS |
| Debt Ratio (0.01%) | PASS |
| Cash Ratio (0.01%) | PASS |
| Receivables Ratio (0.59%) | FAIL |
| Revenue Ratio (0.02%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-28 | 1.82 | Pending | — |
| 2026-04-28 | 1.34 | 1.81 | +35.1% |
| 2026-02-10 | 1.92 | 1.80 | -6.1% |
| 2025-10-28 | 1.64 | 2.26 | +38.0% |
| 2025-07-29 | 1.47 | 1.57 | +6.6% |
| 2025-04-29 | 1.03 | 1.16 | +12.3% |
| 2025-02-10 | 1.55 | 1.43 | -8.0% |
| 2024-10-29 | 0.79 | 0.54 | -31.3% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.3B | $303.3M | $368.0M | $1.2B | $324.2M | 1.52 |
| 2025-12-31 | $1.5B | $299.3M | $414.5M | $1.4B | $384.0M | 1.52 |
| 2025-09-30 | $1.4B | $424.2M | $506.9M | $1.3B | $431.3M | 2.17 |
| 2025-06-30 | $1.2B | $405.0M | $581.5M | $1.1B | $310.8M | 2.09 |
| 2025-03-31 | $1.1B | $158.2M | $257.2M | $979.7M | $216.7M | 0.82 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-19 | CLANCY PAUL J. | Director | 15,000 | $1.4M |
| 2026-05-19 | CLANCY PAUL J. | Director | 15,000 | $1.3M |
| 2026-05-08 | BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | 30,000 | $2.5M |
| 2026-05-06 | CAGNONI PABLO J | Officer | 31,517 | — |
| 2026-05-06 | STEIN STEVEN H. | Officer | 44,124 | — |
| 2026-05-04 | UPADHYAY SUKETU P | Chief Financial Officer | 26,343 | — |
| 2026-04-17 | CAGNONI PABLO J | President | 18,667 | $1.8M |
| 2026-04-17 | CAGNONI PABLO J | President | 18,667 | $1.3M |
| 2026-04-15 | CAGNONI PABLO J | Officer | 27,892 | — |
| 2026-04-15 | STEIN STEVEN H. | Officer | 39,049 | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Baker Bros. Advisors, LP | 30.7M | $3.0B | 0.2% |
| Blackrock Inc. | 19.0M | $1.8B | 0.1% |
| Dodge & Cox Inc. | 12.3M | $1.2B | 0.1% |
| Vanguard Capital Management LLC | 10.9M | $1.1B | 0.1% |
| State Street Corporation | 9.6M | $936.8M | 0.0% |
| Vanguard Portfolio Management LLC | 7.8M | $753.9M | 0.0% |
| AQR Capital Management, LLC | 5.8M | $564.3M | 0.0% |
| Geode Capital Management, LLC | 4.7M | $457.0M | 0.0% |
| LSV Asset Management | 3.9M | $380.9M | 0.0% |
| Invesco Ltd. | 3.9M | $376.1M | 0.0% |
Buy
Hold
Sell
Strong Sell
$15.4B
3.46
0.797
22
$5.4B
$39.4M
+83.8%
2.39
7.75
0.1%
2,844
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-28 | $1.82 | Pending | — |
| 2026-04-28 | $1.34 | $1.81 | +35.1% |
| 2026-02-10 | $1.92 | $1.80 | -6.1% |
| 2025-10-28 | $1.64 | $2.26 | +38.0% |
| 2025-07-29 | $1.47 | $1.57 | +6.6% |
| 2025-04-29 | $1.03 | $1.16 | +12.3% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($107.96, 24 analysts) | |||
| 10 | $985.60 | +$94.00 (10%) | 0.6R |
| 50 | $4,928.00 | +$470.00 (10%) | 0.6R |
| 100 | $9,856.00 | +$940.00 (10%) | 0.6R |
| To Fair Value ($226.00) | |||
| 10 | $985.60 | +$1,274.40 (129%) | 8.6R |
| 50 | $4,928.00 | +$6,372.00 (129%) | 8.6R |
| 100 | $9,856.00 | +$12,744.00 (129%) | 8.6R |
- Elevated short interest (7.75 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| XLV | 0.405 |
| AMGN | 0.375 |
| GILD | 0.369 |
| HQH | 0.365 |
| REGN | 0.350 |
| Ticker | Correlation |
|---|---|
| SPEC.KW | -0.169 |
| SUNC | -0.155 |
| BNO | -0.121 |
| TOMEI.KL | -0.118 |
| HYSNY | -0.116 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500